Estriol

ApprovedSmall molecule

IITF Research Pharma, S.L.U.

Estriol is one of 99 small molecule programs targeting Atrophic Vaginitis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Atrophic VaginitisActive, not recruiting

Pelvic Organ ProlapseActive, not recruiting

AtrophyActive, not recruiting

Breast CancerActive, not recruiting

Multiple SclerosisActive, not recruiting

Hereditary Hemorrhagic TelangiectasiaActive, not recruiting

Atrophic VaginitisPhase 3

Active, not recruiting

Pelvic Organ ProlapseApproved

Active, not recruiting

AtrophyPhase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Multiple SclerosisPhase 2

Active, not recruiting

Hereditary Hemorrhagic TelangiectasiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Estriol

IITF Research Pharma, S.L.U.

Approved

1 2

Tecentriq

Roche

Preclinical

36 3

Zinecard

CChildren's Oncology Group

Preclinical

2 4

Ablavar

LLantheus Medical Imaging

Preclinical

2 5

Tetracycline Hydrochloride

EEuropean Organisation for Research and Treatment of Cancer - EORTC

Preclinical

1 6

Leronlimab

CCytoDyn, Inc.

Preclinical

1 7

Calendula

OOHSU Knight Cancer Institute

Preclinical

1 8

Cyclophosphamide or Azathioprine

SSun Yat-sen University

Preclinical

1 9

Maxigesic

YYonsei University

Preclinical

1 10

Epirubicin-Cyclophosphamide

GGBG Forschungs GmbH

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Atrophy3 trials

Study to Determine Efficacy & Safety of a Low Concentration Estriol (0.005%) in Postmenopausal Vaginal Atrophy.

Completed·IItalfarmaco S.A·Phase 3·NCT04574999·167 enrolled

A Randomized Controlled Phase 2 Study to Determine Lowest Efficacious Dose of Ovestin in Vulvar and Vaginal Atrophy

Withdrawn·AAspen USA Inc·Phase 2·NCT04159493

Study Evaluating the Efficacy and Safety of Three Formulations of Ultra-low Dose Estriol Vaginal Gel (0.005%, 0.002%, 0.0008% Estriol Vaginal Gel) for the Treatment of Vaginal Dryness in Postmenopausal Women With Vulvovaginal Atrophy

Completed·IITF Research Pharma, S.L.U.·Phase 2·NCT02967510·283 enrolled

Multiple Sclerosis3 trials

Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition

Unknown status·UUniversity of California, Los Angeles·Phase 2·NCT01466114·64 enrolled

A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)

Completed·UUniversity of California, Los Angeles·Phase 2·NCT00451204·158 enrolled

Vaginal Estriol in Multiple Sclerosis

Completed·TTexas Tech University Health Sciences Center·Phase 2/3·NCT03774407·21 enrolled

Menopause2 trials

Use of Estriol at Distal Third of Vagina Improving Coital Pain in Post-menopause Women

Completed·UUniversity of Sao Paulo·Phase 1·NCT03116022·125 enrolled

LASER and Radiofrequency and Genitourinary Syndrome of Menopause

Active, not recruiting·FFederal University of São Paulo·N/A·NCT04045379·195 enrolled

Atrophic Vaginitis2 trials

A Trial to Evaluate the Efficacy of Low Dose Vaginal Estrogens in the Treatment of Atrophic Vaginitis

Terminated·MMaire Mac Bride·Phase 3·NCT00816556·63 enrolled

The Treatment Effect of Chinese Herbal Compound Ointment on Atrophic Vaginitis

Unknown status·FFirst Affiliated Hospital, Sun Yat-Sen University·Phase 1·NCT02733731·80 enrolled

Breast Cancer1 trial

A Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting

Completed·IITF Research Pharma, S.L.U.·Phase 2·NCT02413008·61 enrolled

6 more indications

Tics1 trial

The Reciprocal Relations Between Psychosocial Characteristics and the Progression of Vestibulodynia

Completed·MMeir Medical Center··NCT02892214·113 enrolled

Treatment1 trial

Effect of Local Estriol Treatment Before Vaginal Repair Surgery

Active, not recruiting·HHatice Tukenmez Kurnaz·Phase 3·NCT06391372·36 enrolled

Hereditary Hemorrhagic Telangiectasia1 trial

North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)

Completed·JJames Gossage·Phase 2·NCT01408030·123 enrolled

Surgery1 trial

Vaginal Estriol Before and Vaginal Surgery for Prolapse

Unknown status·SSalvatore Caruso·Phase 4·NCT02906111·88 enrolled

Pelvic Organ Prolapse1 trial

Vaginal Estrogens Comparative Trial on Pelvic Organ Prolapse Patients

Completed·UUniversidade Federal do Paraná·Phase 4·NCT03032848·69 enrolled

Unspecified1 trial

Topical Estriol for Vaginal Health

Completed·GGynuity Health Projects·Phase 1·NCT00908570·104 enrolled

Sources

References

[1]
ClinicalTrials.gov — 17 trial records for Estriol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Estriol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Estriol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ITF Research Pharma, S.L.U. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: IITF Research Pharma, S.L.U.

Estriol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Atrophy3 trials

Multiple Sclerosis3 trials

Menopause2 trials

Atrophic Vaginitis2 trials

Breast Cancer1 trial

Tics1 trial

Treatment1 trial

Hereditary Hemorrhagic Telangiectasia1 trial

Surgery1 trial

Pelvic Organ Prolapse1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News